TY -的T1 -颅内狭窄的治疗趋势管理和Post-Sammpris时代(P1.146) JF -神经学乔-神经学六世- 82 - 10补充SP - P1.146盟Swaroop帕瓦尔AU -谭雅图兰AU -乔治Cotsonis AU -首页迈克尔·林恩AU - Rahim伍力盟巴尼船尾AU -科林Derdeyn盟-大卫程序非盟- Marc Chimowitz Y1 - 2014/04/08 UR - //www.ez-admanager.com/content/82/10_Supplement/P1.146.abstract N2 -背景:治疗颅内狭窄已经发展在过去的2年。这个调查试图定义的影响,支架和激进的医疗管理对预防复发性中风颅内狭窄(SAMMPRIS)”的nih资助的专门医师的临床试验治疗趋势管理颅内狭窄。治疗方法:调查选择了1年出版的SAMMPRIS试验结果。(2012)。类似的调查设计后华法林和阿司匹林症状性颅内疾病(WASID)审判时期,另一个nih资助的专门的临床试验是用来比较治疗趋势(pre-SAMMPRIS调查)。调查都被送到神经病学家以及neurointerventionists。post-SAMMPRIS调查解决问题的最大好处医生需要推荐一个新的血管内治疗他们的病人。使用卡方测试数据进行了分析。结果:Post-SAMMPRIS,受访者推荐抗血小板治疗颅内狭窄的数量增加。post-WASID / pre-SAMMPRIS受访者相比,更多post-SAMMPRIS受访者狭窄的首选抗血小板药物前循环(85%比94%,p = 0.0017)和后循环(74%比83%,p = 0.0145)。 The antiplatelet agent most post-SAMMPRIS was the combination of aspirin and clopidogrel. The percentage of neurologists who recommended percutaneous transluminal angioplasty and stenting (PTAS) in > 25% of ICAS patients decreased from pre-SAMMPRIS (12%) to post-SAMMPRIS (6%), while for neurointerventionists, it decreased from (49%) to (17%). DISCUSSION: SAMMPRIS had a major impact on treatment trends of physicians managing patients with intracranial stenosis. In the Post-SAMMPRIS survey, 91% of respondents participating in SAMMPRIS and 82% of overall respondents indicated that the SAMMPRIS results changed the way they managed patients with ICAS.As aggressive medical management coupled with optimal risk factor reduction shows promise in reducing rates of recurrent stroke, a novel endovascular therapy will have to seek newer heights of increasing RRR to gain acceptance by practitioners.Disclosure: Dr. Pawar has nothing to disclose. Dr. Turan has received personal compensation for activities with Gore Laboratories Inc., and Boehringer Ingelheim Pharmaceuticals Inc. Dr. Turan has received research support from Stryker Co., the National Institutes of Health, and AstraZeneca. Dr. Cotsonis has nothing to disclose. Dr. Lynn has nothing to disclose. Dr. Wooley has nothing to disclose. Dr. Stern has received personal compensation for activities with Lippincott Williams & Wilkins. Dr. Stern has received personal compensation in an editorial capacity for The Neurologist. Dr. Derdeyn has received personal compensation for activities with W.L. Gore and Associates, Boston Scientific Corporation, and Target Therapeutics. Dr. Fiorella has received personal compensation for activities with Covidien/ev3, Codman/Micrus/JNJ, NFocus, Vascular Simulations, CSVL, Microvention/Terumo, and Siemens Medical Imaging. Dr. FIorella has received royalty, or license fee, or contractual rights payments from Codman/Micrus/JNJ. Dr. Fiorella has received research support from Microvention and Siemens Medical Imaging. Dr. Chimowitz has received personal compensation for activities with Axio Research, Merck & Co. Inc., and Gore. Dr. Chimowitz has received research support from the National Institute of Neurological Disorders and Stroke, Stryker, and Boston Scientific Corporation.Monday, April 28 2014, 3:00 pm-6:30 pm ER -